MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

Over the past year, millions of automotive enthusiasts and everyday drivers have taken to forums, communities, and expert platforms like AutoGuide to share their passion, ask questions, and exchange ...